Search

Displaying results 5141 - 5150 of 10000 in total
  1. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  2. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    As a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  3. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

  4. Drug

    Onercept

    go.drugbank.com/drugs/DB06495
    Investigational

  5. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  6. Drug

    Lysozyme

    go.drugbank.com/drugs/DB13260
    Investigational

    Categories: Antiinfectives for Systemic Use
  7. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  8. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  9. Drug

    Bergapten

    go.drugbank.com/drugs/DB12216
    Investigational

    Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).

    Categories: Antipsoriatics for Systemic Use, Psoralens for Systemic Use
  10. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental